Clinical trials: CtDNA
Anal Cancer
NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer
This study investigates if circulating tumor DNA can improve the detection of early treatment failure or recurrence in localized squamous cell carcinoma of the anus (SCCA) after curative chemoradiotherapy thereby increasing the…
- Trial name
- NCT05572801
- Testing
- AMR B: HPV positive ctDNA guided imaging in follow-up
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 400 people
- Sponsor
- Aarhus University Hospital
Uterine Cervical Neoplasms
Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
In this study, a large-scale cohort of cervical cancer patients was established in multiple centers. Minimal residual disease(MRD) was assessed by ddPCR detection of HPV E7 gene ctDNA to assess tumor burden and predict the risk…
- Trial name
- NCT05531981
- Testing
- detect HPV E7 ctDNA
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Peking Union Medical College Hospital
Lung Cancer
T790M Plasma Testing Methodology Comparison and Clinical Validation
The aim of this study is to evaluate concordance of T790M mutation plasma testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS.
- Trial name
- ADELOS (NCT02997501)
- Testing
- T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG
- Where
- 7 sites in China
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Lung Neoplasms, EGFR Gene Mutation
Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA
Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
- Trial name
- LiquidLung-A (NCT02629523)
- Testing
- Afatinib
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Chonnam National University Hospital
Non Small Cell Lung Cancer, NSCLC, Stage III
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
- Conditions
- Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
- Trial name
- NCT04585490
- Testing
- Durvalumab, Carboplatin, Pemetrexed
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
Colorectal Cancer
Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer
This study dynamically monitored the prognosis of stage I-IV colorectal cancer patients who could receive radical surgical resection by detecting the levels of polygene methylation in plasma samples from patients with colorectal…
- Trial name
- NCT05444491
- Where
- 7 sites in China
- Volunteers
- 800 people
- Sponsor
- Singlera Genomics Inc.
Non-small Cell Lung Cancer
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
Based on the unique patented MONOD and Methyl Titan methylation sequencing technology on lung cancer tissue and blood samples, a lung cancer MRD monitoring panel is designed.
- Trial name
- NCT05965024
- Where
- China
- Volunteers
- 377 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Follicular Lymphoma, Diffuse Large B Cell Lymphoma
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy…
- Conditions
- Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05255354
- Testing
- ClonoSEQ
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Adaptive Biotechnologies
Pancreatic Ductal Adenocarcinoma (PDAC)
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
This goal of this clinical trial is to learn whether the drug combination of intraperitoneal paclitaxel (chemotherapy given directly into the abdominal cavity) and intravenous NALIRIFOX (chemotherapy given into a vein, including…
- Trial name
- NCT07030283
- Testing
- Paclitaxel, NALIRIFOX
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Colorectal Cancer, Advanced Adenoma
Diagnosis of Colorectal Cancer and Advanced Adenoma Using Cancer-specific Methylation Signatures
Colorectal cancer is a common malignant tumor of the digestive tract. It is still a challenging task to detect colorectal cancer at an early stage.
- Trial name
- NCT03828396
- Where
- China
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Renal Cell Carcinoma
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively.
- Trial name
- NCT05816642
- Testing
- sunitinib or pazopanib, PD-1 inhibitor combined with axitinib
- Where
- China
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Non Small Cell Lung Cancer
Image Mining and ctDNA to Improve Risk Stratification and Outcome Prediction in NSCLC Applying Artificial Intelligence.
Lung cancer is the leading cause of cancer-related death in Europe. Pathological staging is the gold standard, but it can be influenced by neo-adjuvant treatment and number of sampled lymph nodes; it is not feasible in advanced…
- Trial name
- NCT06163846
- Testing
- Assess the role of baseline image mining, ctDNA data and their combination in patient staging and risk stratification
- Where
- Italy
- Volunteers
- 415 people
- Sponsor
- IRCCS San Raffaele
Next-Generation-Sequencing
CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01
In cooperation with the molecular tumor board of the University Hospital Tübingen (UKT), a prospective collection of blood samples during the course of therapy is planned.
- Trial name
- CIRCULATING-01 (NCT05871593)
- Testing
- Molecular genetic diagnostic
- Volunteers
- 200 people
- Sponsor
- University Hospital Tuebingen
Breast Cancer, Neoadjuvant
Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients
1. To explore the predictive value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population; 2. To evaluate the prognostic value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population.
- Conditions
- Breast Cancer, Neoadjuvant, HER2-positive Breast Cancer, Circulating Tumor DNA
- Trial name
- NCT06479460
- Testing
- ctDNA-MRD
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer Female, Stage II Breast Cancer
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.
- Conditions
- Breast Cancer Female, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
- Trial name
- BRAVA (NCT06087120)
- Where
- 3 sites in Indonesia, Vietnam
- Volunteers
- 125 people
- Sponsor
- Gene Solutions
Locally Advanced Unresectable Uveal Melanoma
Neoadjuvant Tebentafusp for Uveal Melanoma
This is a prospective, single arm, phase II clinical trial of neoadjuvant Tebentafusp (KIMMTRAK®) in patients with locally advanced primary uveal melanoma.
- Trial name
- NCT06414590
- Testing
- Tebentafusp-Tebn
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Thomas Jefferson University
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis
Collection of ctDNA and TCR data to predict the efficacy and prognosis of brain radiotherapy in patients with brain metastases from non-small cell lung cancer (NSCLC) in a comprehensive manner
- Trial name
- NCT05737589
- Testing
- Whole-brain radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xiaorong Dong
Metastatic Colorectal Cancer (CRC)
ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"
This study is a phase II, open-label, multicenter clinical trial designed to evaluate two different treatment options for patients with metastatic colorectal cancer whose disease has progressed after standard therapies.
- Trial name
- ROMANCE - GOIM (NCT07381764)
- Testing
- Erbitux (Cetuximab), Bevacizumab, Irinotecan
- Where
- 26 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Gruppo Oncologico Italia Meridionale
Bladder Cancer, Bladder Cancer, Metastatic
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
Immunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer.
- Trial name
- TOMBOLA (NCT04138628)
- Testing
- Atezolizumab
- Where
- 5 sites in Denmark
- Volunteers
- 154 people
- Sponsor
- Jørgen Bjerggaard Jensen
Gastric Cancer
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
Recently, a number of clinical studies were carried out to evaluate the therapeutic effects of PD-1 antibodies combined with chemotherapy as preoperative neoadjuvant therapy of gastric cancer (GC) worldwide.
- Trial name
- NCT05594381
- Testing
- Sintilimab
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University